Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Dual and context-dependent role of the interleukin-33/soluble suppression of tumorigenicity 2 axis in obesity and adipose tissue inflammation

Casado M., Gómez-Ambrosi J., Ramírez B., Becerril S., Rodríguez A., Valentí V.

Animal Study on Type 2 Diabetes, Chronic Inflammation, published in Mol Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Med (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41814156
PMCID
PMC13094069
DOI
10.1186/s10020-026-01454-z

Abstract (original English)

BACKGROUND: Obesity is increasingly recognized as a state of chronic, unresolved inflammation in which the interleukin (IL)-33/suppression of tumorigenicity 2 (ST2) axis may represent a key immunometabolic regulator. OBJECTIVE: We investigated circulating concentrations and adipose tissue expression levels of IL-33 and its soluble receptor sST2 in obesity and type 2 diabetes, and evaluated their functional effects on adipocytes and macrophages. RESULTS: Circulating IL-33 levels were significantly elevated (P < 0.01) in obesity compared with controls, being positively (P < 0.01) correlated with body mass index and HOMA-IR and negatively (P < 0.05) with HDL cholesterol. Conversely, sST2 was reduced in obesity (P < 0.05) and inversely associated with body fat percentage (P < 0.001) and fibrinogen levels (P < 0.05), suggesting enhanced IL-33 bioavailability. Visceral adipose tissue (VAT) from subjects with obesity exhibited increased IL-33 gene and protein expression levels (P < 0.01, for both). Functional analyses show that IL-33 induced (P < 0.01) the expression of adiponectin, omentin (ITLN1), and IL13 in adipocytes and attenuated (P < 0.01) LPS-driven IL1B and TNF expression. In macrophages, adipocyte-conditioned medium (ACM) from people with obesity strongly suppressed (P < 0.01) IL33 expression, while exogenous IL-33 counteracted pro-inflammatory activation, reducing LPS- and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAdipocytesMacrophagesAnimalsHumansDiabetes Mellitus, Type 2ObesityInflammationAdultMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research